Home monitoring program benefits children after Norwood palliation
Home monitoring program benefits children after Norwood palliation
CHICAGO — Use of an interdisciplinary single-ventricle task force team employing home monitoring in the care of children with congenital heart disease after Norwood palliation was associated with a reduction in complications and improved weight, researchers reported.
The researchers measured the clinical outcomes of stage II admission and gauged the approval of parents and cardiologists. The study population was divided into two cohorts, one with Norwood surgery dates before the development of the single-ventricle task force (pre-SVTF) and one interventional cohort (post-SVTF). Post-SVTF data included surveys from parents and cardiologists on the effectiveness of the program.
The results were presented at the American College of Cardiology Scientific Session and published in Pediatric Cardiology.
Compared with the pre-SVTF group, the post-SVTF group experienced fewer complications after stage II (18.4% vs. 34.1%; P = .02) and had higher weight for-age z scores at stage II (–1.5 plus or minus 0.97 vs. –1.58 plus or minus 1.34; P = .02). In addition, a written red-flag action plan given to parents at the time of Norwood discharge was independently associated with higher weight at stage II (β = 0.42; P = .04) and higher weight for-age z score (β = 0.48; P = .02)
“Parents encouraged expansion of the team approach to cover all children with congenital heart disease,” Ashraf Harahsheh, MD, from Children’s National Health System, Washington, D.C., and colleagues wrote in the paper and the abstract. “There was approval within the larger group of cardiologists for the development of a subspecialized task force to care for the complex [single-ventricle] patient population.” – by Tracey Romero
References:
Harahsheh A, et al. Poster 1109-198. Presented at: American College of Cardiology Scientific Session; April 2-4, 2016; Chicago.
Harahsheh A, et al. Pediatr Cardiol. 2016;doi:10.1007/s00246-016-1366-y.
Disclosure: Harahsheh reports no relevant financial disclosures.